A brief post on some interviews I gave recently on esketamine for treatment-resistant depression and depression in women who have problems getting pregnant.
The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.
Janssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.
The problem of withdrawal syndromes and emotional blunting occurring with prolonged antidepressant treatment is constantly underestimated by clinicians.
An article on the front page of the New York Times on April 7, 2018, has fueled the debate over antidepressants again.
In the March issue of Nature Biotechnology, Teresa Evans of the University of San Antonio, Texas, and co-authors point out that there is “Evidence for a mental health crisis in graduate education”.
A brief report from the first congress of the International Society for Nutritional Psychiatry Research (ISNPR), which emphasizes the importance of nutrition.
Two overviews in JAMA show that medical students and residents are suffering terrifyingly frequently from depression and depressive symptoms.